{"DataElement":{"publicId":"3158792","version":"1","preferredName":"Person Histologic Ovarian Neoplasm Breast Neoplasm Non-Hodgkin Lymphoma Clinical Trial Eligibility Criteria Histologic Ovarian Neoplasm Breast Neoplasm Non-Hodgkin Lymphoma Type","preferredDefinition":"the type of histologically confirmed ovarian cancer (malignant, primary or metastatic neoplasm involving the ovary). breast cancer (a malignant neoplasm of the breast parenchyma), or non-Hodgkin lymphoma (characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss) as criteria required to to be eligible to participate in a clinical trial.","longName":"3158784v1.0:3158785v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3158784","version":"1","preferredName":"Person Histologic Ovarian Neoplasm Breast Neoplasm Non-Hodgkin Lymphoma Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person having histologically confirmed ovarian cancer (malignant, primary or metastatic neoplasm involving the ovary). breast cancer (a malignant neoplasm of the breast parenchyma), or non-Hodgkin lymphoma (characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss) as criteria required to to be eligible to participate in a clinical trial.","longName":"2236731v1.0:3158782v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3158782","version":"1","preferredName":"Histologic Ovarian Neoplasm Breast Neoplasm Non-Hodgkin Lymphoma Clinical Trial Eligibility Criteria","preferredDefinition":"Of or relating to histology.:A benign or malignant, primary or metastatic neoplasm involving the ovary.:A benign or malignant neoplasm of the breast parenchyma.  It can originate from the ducts, lobules or the breast adipose tissue.  Breast neoplasms are much more common in females than males. -- 2003:Distinct from Hodgkin's lymphoma both morphologically and biologically, NHL lymphoma is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss.  The clinical course varies according to the morphologic type.  NHL is clinically classified as indolent, aggressive, or having a variable clinical course.  NHL can be of B-or T-/NK-cell lineage. --2003:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3158782v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Ovarian Neoplasm","conceptCode":"C4984","definition":"A benign, borderline, or malignant neoplasm involving the ovary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Breast Neoplasm","conceptCode":"C2910","definition":"A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-5467-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"ONEDATA","dateModified":"2010-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-5478-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3158785","version":"1","preferredName":"Histologic Ovarian Neoplasm Breast Neoplasm Non-Hodgkin Lymphoma Type","preferredDefinition":"the type of Histologic Ovarian Neoplasm, Breast Neoplasm, or Non-Hodgkin Lymphoma.","longName":"3158785v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"500","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Triple-negative breast cancer with BRCA-positive mutation and with metastasis to distant sites.","valueDescription":"Triple-negative breast cancer with BRCA-positive mutation and with metastasis to distant sites.","ValueMeaning":{"publicId":"3185160","version":"1","preferredName":"Triple-negative breast cancer with BRCA-positive mutation and with metastasis to distant sites.","longName":"3185160","preferredDefinition":"Triple-negative breast cancer with BRCA-positive mutation and with metastasis to distant sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4F5C1B-D867-7FFF-E040-BB89AD431A4E","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4F5C1B-D880-7FFF-E040-BB89AD431A4E","beginDate":"2010-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (no requirement for BRCA status)","valueDescription":"Primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (no requirement for BRCA status)","ValueMeaning":{"publicId":"3170957","version":"1","preferredName":"Primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (no requirement for BRCA status)","longName":"3170957","preferredDefinition":"Primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (no requirement for BRCA status)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CDB45F-327A-3F1D-E040-BB89AD435250","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CDB45F-3293-3F1D-E040-BB89AD435250","beginDate":"2010-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"Primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer","valueDescription":"Primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer","ValueMeaning":{"publicId":"3158786","version":"1","preferredName":"Primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer","longName":"3158786","preferredDefinition":"Primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-549E-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94CE5395-54B7-0C9F-E040-BB89AD434EB3","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"ONEDATA","dateModified":"2010-11-11","deletedIndicator":"No"},{"value":"BRCA-positive ovarian cancer (Deleterious BRCA1/2 mutation or a BRCAPRO score of >= 30%. Documentation must be provided prior to enrolling in the study)","valueDescription":"BRCA-positive ovarian cancer (Deleterious BRCA1/2 mutation or a BRCAPRO score of >= 30%. Documentation must be provided prior to enrolling in the study)","ValueMeaning":{"publicId":"3158787","version":"1","preferredName":"BRCA-positive ovarian cancer (Deleterious BRCA1/2 mutation or a BRCAPRO score of >= 30%. Documentation must be provided prior to enrolling in the study)","longName":"3158787","preferredDefinition":"BRCA-positive ovarian cancer (Deleterious BRCA1/2 mutation or a BRCAPRO score of >= 30%. Documentation must be provided prior to enrolling in the study)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-54C1-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94CE5395-54DA-0C9F-E040-BB89AD434EB3","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"ONEDATA","dateModified":"2010-11-11","deletedIndicator":"No"},{"value":"Low-grade lymphoid malignancies (NHL)","valueDescription":"Low-grade lymphoid malignancies (NHL)","ValueMeaning":{"publicId":"3158788","version":"1","preferredName":"Low-grade lymphoid malignancies (NHL)","longName":"3158788","preferredDefinition":"Low-grade lymphoid malignancies (NHL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-54E5-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94CE5395-54FE-0C9F-E040-BB89AD434EB3","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"ONEDATA","dateModified":"2010-11-11","deletedIndicator":"No"},{"value":"Triple-negative breast cancer with BRCA-negative or BRCA-unknown mutation and with metastasis to distant sites.","valueDescription":"Triple-negative breast cancer with BRCA-negative or BRCA-unknown mutation and with metastasis to distant sites.","ValueMeaning":{"publicId":"3185162","version":"1","preferredName":"Triple-negative breast cancer with BRCA-negative or BRCA-unknown mutation and with metastasis to distant sites.","longName":"3185162","preferredDefinition":"Triple-negative breast cancer (documented ER negative, PR negative, and Her2/neu negative from the original pathology report, per ASCO/CAP guidelines (47, 48)) with BRCA-negative or BRCA-unknown mutation and with metastasis to distant sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4FAA2C-BDF4-A1CC-E040-BB89AD43231C","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4FAA2C-BE0D-A1CC-E040-BB89AD43231C","beginDate":"2010-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-5489-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"ALAIS","dateModified":"2011-01-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Indicate Cancer histology:","type":"Preferred Question Text","description":"Indicate Cancer histology:","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94CE5395-556D-0C9F-E040-BB89AD434EB3","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-11","modifiedBy":"CAMPBELB","dateModified":"2010-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}